Eribulin

Drugbox
IUPAC_name = 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9"H",15"H"-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4"H")-one

---

width = 300
CAS_number = 253128-41-5
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem =
DrugBank =
chemical_formula =
C=40 | H=59 | N=1 | O=11
molecular_weight = 729.90 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
licence_EU =
licence_US =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Eribulin (INN, codenamed E7389) is an investigational anti-cancer drug. It is currently being investigated by Eisai for the third-line treatment of advanced breast cancer in patients who were pretreated with anthracycline, taxane and capecitabine. Eribulin is a synthetic analogue of halichondrin B, a potent, natural mitotic inhibitor with an unique mechanism of action found in the "Halichondria" genus of sponges.cite journal |author=Kuznetsov G, Towle MJ, Cheng H, "et al" |title=Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 |journal=Cancer Res |volume=64 |issue=16 |pages=5760–6 |year=2004 |month=August |pmid=15313917|doi=10.1158/0008-5472.CAN-04-1169]

On February 1, 2008, Eisai announced a change in the schedule for submission to the US Food and Drug Administration (FDA) of a New Drug Application (NDA) for eribulin. [cite web |url=http://www.drugs.com/nda/e7389_080201.html |title=Drugs.com, Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application |accessdate=2008-02-06 |format= |work= ]

References